European Pharmaceutical Review
SEPTEMBER 28, 2023
According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), more than 600 essential medicines are at risk if a proposed restriction on the use of fluorinated substances, per- and polyfluoroalkyl substances (PFAS) across pharmaceutical manufacturing in the EEA, is implemented.
European Pharmaceutical Review
OCTOBER 12, 2023
September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Research by the Confederation of British Industry (CBI) , released in September this year, highlighted progress for UK manufacturing in its latest Industrial Trends Survey. Meath opened last month.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
MAY 1, 2024
Our Ludwigshafen site serves as a centre of excellence for both research and development and pharmaceutical manufacturing and will play a critical role in AbbVie’s future growth,” stated Azita Saleki-Gerhardt , PhD, Executive Vice President, Chief Operations Officer. The new R&D building in Germany is expected to completed in 2027.
Medico Reach
FEBRUARY 8, 2023
The global pharmaceutical manufacturing market stood at USD 405.52 The paradigm shift towards integrated, intelligent, and data-rich technologies is propelling the growth of medicines manufacturing. billion by 2027. The Grand View Research published a report highlighting the stark growth prospects of the pharma industry.
Clarivate
AUGUST 20, 2024
In 2025, CMS will select another 15 Part D drugs for negotiations that will take effect in 2027. Although the initial set of drugs included for negotiations was limited to ten, the scope of this program will expand over time.
Expert insights. Personalized for you.
105 
Let's personalize your content